BiotechTube

Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + Dexamethasone

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sarcoma

Conditions

Sarcoma, Nausea, Vomiting

Trial Timeline

Dec 1, 2006 → Jun 1, 2011

NCT ID
NCT00410488

About Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + Dexamethasone

Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + Dexamethasone is a pre-clinical stage product being developed by Eisai for Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00410488. Target conditions include Sarcoma, Nausea, Vomiting.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00410488Pre-clinicalCompleted

Competing Products

20 competing products in Sarcoma

See all competitors
ProductCompanyStageHype Score
Tc99m-tilmanoceptNavidea BiopharmaceuticalsPhase 1
25
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
33
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
33
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
33
AbemaciclibEli LillyPhase 2
52
Abemaciclib + PlaceboEli LillyPhase 3
77
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
77
PLX3397 + sirolimusDaiichi SankyoPhase 1/2
41
exatecan mesylateDaiichi SankyoPhase 2
52
efatutazoneDaiichi SankyoPhase 2
52
soblidotinDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
Fluzoparib+ DalpiciclibSun PharmaceuticalPhase 2
52
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
52
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+VincristineSun PharmaceuticalPhase 2
52
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
52
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
77
EribulinEisaiPhase 2
52
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85